GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Role of Integrins and bone matrix in prostate cancer

$281,501
Tatiana V Byzova · Cleveland Clinic Lerner Com-Cwru · R01 · FY2011 · CA

Prostate Oncology

$281,493
Max S. Wicha · University Of Michigan At Ann Arbor · P30 · FY2016 · CA

Targeting immunosuppression blockade to T cells for cancer immunotherapy

$281,457
Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2013 · CA

Systemic Inhibition of Monocyte Chemoattractant Protein-1 (MCP-1; CCL2)

$281,447
Robert Loberg · University Of Michigan At Ann Arbor · P50 · FY2012 · CA

Tak1, a novel prostate cancer tumor suppressor

$281,438
Scott D Cramer · University Of Colorado Denver · R01 · FY2013 · CA

Project 4 - Study of KSHV Carcinogenesis

$281,390
Dirk P Dittmer · Univ Of North Carolina Chapel Hill · P01 · FY2020 · CA

ENDOTHELIAL GROWTH FACTOR IN PROSTATE CANCER METASTASIS

$281,385
University Of Virginia Charlottesville · R01 · FY2004 · CA

ENDOTHELIAL GROWTH FACTOR IN PROSTATE CANCER METASTASIS

$281,385
University Of Virginia Charlottesville · R01 · FY2001 · CA

ENDOTHELIAL GROWTH FACTOR IN PROSTATE CANCER METASTASIS

$281,385
University Of Virginia Charlottesville · R01 · FY2003 · CA

ENDOTHELIAL GROWTH FACTOR IN PROSTATE CANCER METASTASIS

$281,385
University Of Virginia Charlottesville · R01 · FY2002 · CA

Biomarker-Driven Strategies to Overcome Immunotherapy Resistance in STK11-Deficient NSCLC

$281,370
Jacob Marcus Kaufman · Ohio State University · K08 · FY2024 · CA

Biomarker-Driven Strategies to Overcome Immunotherapy Resistance in STK11-Deficient NSCLC

$281,370
Jacob Marcus Kaufman · Ohio State University · K08 · FY2025 · CA

Spatial patterning of branching morphogenesis

$281,362
Celeste M Nelson · Princeton University · R01 · FY2012 · GM

Enhancing Radiation Therapy: Vascular Targeting Agents

$281,312
Dietmar W Siemann · University Of Florida · R01 · FY2007 · CA

Integrating innate and adaptive immunity in cancer therapy

$281,279
Nejat K Egilmez · State University Of New York At Buffalo · R01 · FY2013 · CA

Mechanisms Determining Stromal Pten Suppression of IVIammary Tumorigenesis

$281,249
Michael C Ostrowski · Ohio State University · P01 · FY2013 · CA

Suppression of Mammary Tumorigenesis by Stromal p53

$281,241
Gustavo Walter Leone · Ohio State University · P01 · FY2013 · CA

Shaping the Microenvironment by DPEP1 Facilitates Adenoma Progression

$281,177
Robert J Coffey · Vanderbilt University Medical Center · U54 · FY2025 · CA

Co-Evolution Mechanisms of Pre-Cancer-Immune Interactions in Shaping Adaptive Cytotoxicity and Myeloid-Derived Suppression

$281,177
Ken S Lau · Vanderbilt University Medical Center · U54 · FY2025 · CA

Gene product delivery by engineered somatic cells

$281,105
Joy A Phillips · Sidney Kimmel Cancer Center · R21 · FY2007 · EB

Project 2: Heparan Sulfate Proteoglycans in Prostate Cancer Bone Metastasis

$281,091
Mary C Farach-Carson · Cedars-Sinai Medical Center · P01 · FY2017 · CA

Regulation of Fibronectin Matrix Assembly by uPAR

$281,080
Paula J Mc Keown-Longo · Albany Medical College · R01 · FY2010 · CA

Regulation of Fibronectin Matrix Assembly by uPAR

$281,080
Paula J Mc Keown-Longo · Albany Medical College · R01 · FY2009 · CA

SUBNUCLEAR TARGETING AND TRANSCRPTIONAL CONTROL DURING INTERPHASE AND MITOSIS IN

$281,070
Gary S. Stein · Univ Of Massachusetts Med Sch Worcester · P01 · FY2007 · CA

Enabling NF-kB Signal Transduction Studies in Primary Multiple Myeloma Cells

$281,059
Shigeki Miyamoto · University Of Wisconsin-Madison · R01 · FY2012 · CA